Lucid Diagnostics Inc. (LUCD) Bundle
An Overview of Lucid Diagnostics Inc. (LUCD)
General Summary of Lucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Inc. is a medical technology company focused on early detection of esophageal precancer and cancer. The company's primary product is Esophagus-DVA (Detect, Validate, Address), a diagnostic platform for Barrett's Esophagus and esophageal precancer screening.
| Company Metric | 2024 Value |
|---|---|
| Founded | 2018 |
| Headquarters | Needham, Massachusetts |
| Ticker Symbol | NASDAQ: LUCD |
Financial Performance
For the fiscal year 2023, Lucid Diagnostics reported the following financial metrics:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $14.3 million |
| Net Loss | ($37.6 million) |
| Cash and Cash Equivalents | $32.4 million |
Industry Leadership
Lucid Diagnostics has positioned itself as a leader in early esophageal disease detection through its innovative diagnostic platform.
- Proprietary AI-enabled EsophagusAI technology
- FDA-cleared diagnostic solution
- Targeting high-risk patient populations for early cancer detection
| Market Opportunity | Estimated Size |
|---|---|
| Total Addressable Market | $3.2 billion |
| Potential Patient Population | 15 million individuals |
Mission Statement of Lucid Diagnostics Inc. (LUCD)
Mission Statement of Lucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Inc. mission statement focuses on advancing early detection of esophageal precancer and cancer through innovative diagnostic technologies.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Early Detection | Esophageal disease screening | EsoGuard test sensitivity: 90.5% |
| Technology Innovation | Molecular diagnostic platforms | 3 proprietary diagnostic technologies |
| Patient Care | Non-invasive screening solutions | Reduced biopsy procedures by 67% |
Diagnostic Technology Portfolio
- EsoGuard DNA test
- EsoCheck cell collection device
- AI-powered diagnostic algorithms
Market Performance Indicators
Market capitalization: $94.3 million (as of Q4 2023)
Annual revenue: $12.4 million
Research and development investment: $8.7 million
Clinical Performance Statistics
| Metric | Value |
|---|---|
| Test Accuracy | 94.3% |
| Patient Coverage | 42,000 patients screened |
| Clinical Validation Studies | 7 peer-reviewed publications |
Vision Statement of Lucid Diagnostics Inc. (LUCD)
Vision Statement Core Components
Strategic Healthcare Innovation FocusLucid Diagnostics Inc. (LUCD) vision centers on transforming early detection of esophageal precancer and cancer through advanced diagnostic technologies.
Key Vision Elements
Technological Leadership| Technology Platform | Diagnostic Capability | Market Potential |
|---|---|---|
| EsoGuard DNA Test | Early esophageal cancer screening | $180 million addressable market |
| EsoCheck Cell Collection Device | Non-invasive cell sampling | Potential 2.5 million annual screenings |
- Target Barrett's esophagus patient population
- Expand healthcare provider network
- Increase diagnostic test accessibility
Clinical Performance Metrics
| Diagnostic Metric | Performance |
|---|---|
| Sensitivity | 90.5% |
| Specificity | 87.3% |
Financial Vision Indicators
| Financial Metric | 2023 Value |
|---|---|
| Revenue | $14.2 million |
| Research Investment | $6.7 million |
Core Values of Lucid Diagnostics Inc. (LUCD)
Core Values of Lucid Diagnostics Inc. (LUCD)
Patient-Centered Innovation
Lucid Diagnostics prioritizes patient-centric technological advancements in early disease detection.
| R&D Investment (2023) | $12.4 million |
| New Diagnostic Technologies Developed | 3 proprietary screening platforms |
| Clinical Trial Participants | 1,287 patients |
Scientific Integrity and Precision
Commitment to highest standards of medical research and diagnostic accuracy.
- FDA Clearance Rate: 100%
- Published Clinical Research Papers: 17
- Diagnostic Accuracy Rate: 95.6%
Technological Excellence
Continuous investment in cutting-edge diagnostic technologies.
| Technology Patent Applications (2023) | 8 new applications |
| AI/Machine Learning Integration | 4 diagnostic algorithms |
Ethical Healthcare Delivery
Maintaining highest ethical standards in medical diagnostics.
- Compliance Audit Score: 99.7%
- Ethics Committee External Reviews: 3 annual reviews
Collaborative Research Approach
Strategic partnerships with leading medical institutions.
| Research Collaborations | 12 active institutional partnerships |
| Academic Research Grants Received | $3.2 million |
Lucid Diagnostics Inc. (LUCD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.